【摘要】 本工作着重研究了可用于PTCA(Percutaneous transluminal coronary angioplasty)后冠状动脉再狭窄防治的放射性标记化合物188Re-MAG3的制备,并与Na188ReO4的小鼠体内生物分布加以比较。结果表明,在TechneScan MAG3锝药盒中加入酒石酸亚锡,控制标记条件,188Re-MAG3的标记率可大于98％。188Re-MAG3在小鼠体内的血液清除明显快于Na188ReO4,甲状腺和胃肠道吸收明显低于Na188ReO,标记物主要经肾脏通过尿液排出体外。为降低PTCA后冠脉再狭窄的发生率,与Na188ReO4相比,188Re-MAG3更适于临床应用。更多还原

【Abstract】 188Re-MAG3, a potential radiopharmaceutical for restenosis treatment after PTCA, was prepared with commercially available TechneScan MAG3 kit. The labeling yield of 188Re-MAG3 was more than 98 % under the optimal labeling condition. The data revealed that stability of 188Re-MAG3 in reaction medium and in saline was better than in bovine serum. Compared to Na188ReO4, the blood clearance of 188Re-MAG3 was faster and the uptake in thyroid and stomach was lower. The radiolabeled compound was excreted rapidly through urinary system.188Re-MAG3 is promising for clinical trial instead of Na188ReO4.更多还原